Barcelona, España & Melbourne, FL, EE. UU.
(“Devicare”), a pioneering pharmaceutical company specializing in urology, today announces the successful acquisition of IP-6 International, Inc. (“IP-6 International”), a respected U.S.-based nutritional supplement company and manufacturer of the well-known IP6 Gold® brand. This transaction marks Devicare’s first acquisition outside of Spain and represents a major milestone in the company’s international growth strategy.
The acquisition positions Devicare for a meaningful entry into the United States market, the largest and most dynamic pharmaceutical and nutraceutical market in the world. Devicare intends to leverage its proven scientific expertise and commercial infrastructure to expand IP-6 International’s footprint globally, while also introducing Devicare’s broader portfolio of innovative urology products to new audiences in the U.S.
“IP-6 International is a company with a long-standing reputation for high-quality, scientifically informed nutritional products made in the USA,” said Rosendo Garganta, CEO of Devicare. “This acquisition represents a natural extension of our mission to bring science-driven health solutions to patients and healthcare professionals worldwide. By combining Devicare’s expertise in urology with IP-6 International’s established presence and product portfolio, we are creating a strong platform for sustainable growth in the U.S. market and beyond.”
Founded in 2002, IP-6 International has built global recognition around its flagship product, IP6 Gold®, a premium formula combining inositol hexaphosphate (IP6)—a well-known compound extensively studied and used by Devicare in many of its products—with inositol derived from non-GMO rice bran. Manufactured under strict quality standards, IP6 Gold® is widely trusted by both healthcare professionals and consumers. The acquisition enhances Devicare’s portfolio with a brand that is not only highly complementary to its scientific foundations, but also provides a strategic lever for expansion in North America and other key regions.
“We are excited about the opportunities this partnership brings,” said Tom Sokoloff, President and CEO of IP-6 International. “Devicare shares our commitment to quality and evidence-based products, and we believe this collaboration will accelerate the reach and impact of IP6 Gold®, while ensuring continuity, innovation, and excellence for our customers.”
This acquisition lays the groundwork for Devicare to strengthen its presence across the United States and to use this strategic platform to expand its global reach, reinforcing its mission to improve patient outcomes in urolithiasis and other areas of urinary health. Together with its existing portfolio and recent international launches, Devicare continues to consolidate its leadership position in the field of urology.
About Devicare
Devicare, S.L. is a pharmaceutical company headquartered in Barcelona, Spain, dedicated to developing clinically proven solutions in urology. With products marketed in more than 60 countries worldwide, and supported by robust scientific evidence and intellectual property, Devicare’s mission is to transform the management of kidney stone disease and improve patients’ quality of life. The acquisition of IP-6 International represents a significant step in the company’s global expansion strategy.
About IP-6 International, Inc.
IP-6 International, Inc., based in Melbourne, Florida, is the exclusive producer of IP6 Gold® and Red Yeast Rice Gold®, products recognized for their high purity and strong commitment to quality. Founded in 2002, the company has built a solid U.S. distribution network and earned strong trust among healthcare professionals through rigorous manufacturing standards and transparent sourcing.
Media Contacts
Devicare, S.L.
Rosendo Garganta, CEO
Email: rgarganta@devicare.com
IP-6 International, Inc.
Tom Sokoloff, Presidente y CEO
Email: info@IP6Gold.com
